Evidence map›Paper›PMID 41925892›Full record

ArticleBreast cancer research and treatment2026

Kidney function changes associated with trastuzumab use in women with breast cancer: a retrospective cohort study.

Amber O Molnar, Eric McArthur, Sarah E Bota, Kathryn Stirling, Jaffa Romain, Darryl P Leong, Som D Mukherjee, Abhijat Kitchlu, Michael Walsh

Abstract read
PubMed Publisher
In one paragraph

Article in Breast cancer research and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Amber O MolnarDivision of Nephrology, Department of Medicine, McMaster University, 3rd Floor Marian Wing, St Joseph's Hospital, 50 Charlton Ave, Hamilton, ON, L8N 4A6, Canada. amolnar@stjosham.on.ca.
Eric McArthurICES, Toronto, ON, Canada.
Sarah E BotaICES, Toronto, ON, Canada.
Kathryn StirlingICES, Toronto, ON, Canada.
Jaffa RomainICES, Toronto, ON, Canada.
Darryl P LeongPopulation Heath Research Institute, McMaster University/Hamilton Health Sciences, Hamilton, ON, Canada.
Som D MukherjeeDepartment of Oncology, McMaster University, Hamilton, ON, Canada.
Abhijat KitchluDivision of Nephrology, Department of Medicine, University Health Network, University of Toronto, Toronto, ON, Canada.
Michael WalshDivision of Nephrology, Department of Medicine, McMaster University, 3rd Floor Marian Wing, St Joseph's Hospital, 50 Charlton Ave, Hamilton, ON, L8N 4A6, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeHigher concentrations of human epidermal growth receptor 2 (HER2) may cause chronic kidney disease. We sought to determine if trastuzumab (a HER2 inhibitor) may be kidney protective.

methodsRetrospective cohort study using administrative datasets. Women from Ontario, Canada with new stage 1-3 breast cancer between April 2009 and March 2019 were included. We matched trastuzumab users (n = 6,557) 1:1 with non-users on baseline eGFR, urine albumin-to-creatinine ratio (ACR), heart failure and propensity score. Change in eGFR was examined using linear mixed models. Secondary outcomes of ≥ 30 and ≥ 40% eGFR decline, incident eGFR < 60 mL/min/1.73 m

resultsThe linear mixed model showed no significant interaction between treatment with trastuzumab and time (estimate 0.11, 95% CI -0.01 to 0.23, ml/min/1.73 m

conclusionTrastuzumab was not associated with change in eGFR over 3 years but was associated with increased risk of ≥ 30% and ≥ 40% eGFR decline and new eGFR < 60 mL/min/1.73 m

Indexed as

Antineoplastic Agents, ImmunologicalBreast NeoplasmsKidneyRenal Insufficiency, ChronicTrastuzumabAdultAgedErb-b2 Receptor Tyrosine KinasesFemaleGlomerular Filtration RateHeart FailureHumansMiddle AgedOntarioRetrospective StudiesAntineoplastic Agents, ImmunologicalERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesTrastuzumabCKDCohortHeart failureTrastuzumab

Identifiers

PMID41925892

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.